SOURCE: INSYS Therapeutics

Insys Therapeutics

May 07, 2014 07:00 ET

Insys Therapeutics to Present at 2014 UBS Global Healthcare Conference

PHOENIX, AZ--(Marketwired - May 7, 2014) - Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the company will present at the 2014 UBS Global Healthcare Conference on May 19-21, 2014 at the Sheraton New York Times Square Hotel in New York City.

Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will host the presentation on Tuesday, May 20, 2014 at 2:30 p.m. EDT.

To listen to the audio webcast of this presentation during the event, please visit: A replay of this webcast will be available for 30 days after the initial presentation.

About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative products for supportive care of cancer and pain patients. Using its proprietary sublingual spray technology and its capability to develop pharmaceutical cannabinoids, the company addresses the clinical shortcomings of existing commercial products. The company currently markets two products, Subsys, which is sublingual Fentanyl spray for break through cancer pain, and a generic version of Dronabinol (THC) capsules. The company plans to file a New Drug Application (NDA) for an oral liquid formulation of Dronabinol in the second half of 2014 and believes it is a clinically superior product to current Dronabinol capsules. The company is developing a pipeline of sublingual sprays, as well as pharmaceutical CBD.

Contact Information